R&D Purity, potency, and safety – affordably – in stem cell ther... In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of s
News Teva, Sanofi score well with anti-TL1A drug in IBD test Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.